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Remission of diabetes mellitus in cats cannot be predicted by the
arginine stimulation test
Abstract
Background: Cats with diabetes mellitus frequently achieve clinical remission, suggesting residual β-cell
function. Responsiveness of β-cells to arginine persists the longest during diabetes progression, making
the intravenous arginine stimulation test (IVAST) a useful tool to assess residual insulin and glucagon
secretion. Hypothesis: Diabetic cats with and without remission will have different arginine-induced
insulin or glucagon response. Animals: Seventeen cats with diabetes, 7 healthy cats. Methods: Blood
samples collected on admission and during subsequent IVAST. Glucose, insulin, and glucagon were
measured. Response to IVAST was assessed by calculating the insulin and glucagon area under the
curve (AUC) and the AUC glucagon-to-insulin ratio. Diabetic cats were treated with insulin and were
followed for 18 weeks. Remission was defined as normoglycemia and disappearance of clinical signs of
diabetes for ≥4 weeks, without requiring insulin. Results: Seven diabetic cats (41%) achieved remission.
On admission, blood glucose concentration was significantly lower in cats with remission (median,
389 mg/dL; range, 342-536 mg/dL) than in those without remission (median, 506 mg/dL; range,
266-738 mg/dL). After IVAST, diabetic cats with remission had higher AUC glucagon-to-insulin
ratios (median, 61; range, 34-852) than did cats without remission (median, 26; range, 20-498); glucose,
insulin, and glucagon AUCs were not different. Diabetic cats had lower insulin AUC than did healthy
cats but comparable glucagon AUC. Conclusions and Clinical Importance: Diabetic cats with and
without remission have similar arginine-stimulated insulin secretion on admission. Although cats with
remission had lower blood glucose concentrations and higher AUC glucagon-to-insulin ratios, large
overlap between groups prevents use of these parameters in clinical practice.
	   1	  
REMISSION OF DIABETES MELLITUS IN CATS CANNOT BE 1	  
PREDICTED BY ARGININE STIMULATION TEST 2	  
 3	  
Flurin Tschuor, Eric Zini, Stefan Schellenberg, Monique Wenger, Karin 4	  
Kaufmann, Daniela Furrer, Thomas A. Lutz, and Claudia E. Reusch 5	  
From the Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 6	  
Winterthurerstrasse 260, 8057 Zurich, Switzerland (Tschuor, Zini, Schellenberg, Wenger, 7	  
Kaufmann, Reusch); and Institute of Veterinary Physiology, Vetsuisse Faculty, University of 8	  
Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland (Furrer, Lutz). 9	  
 10	  
Short title: diabetic remission in cats. 11	  
 12	  
Correspondance to: Prof. Claudia E. Reusch, Clinic for Small Animal Internal Medicine, 13	  
Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland. 14	  
E-mail: creusch@vetclinics.uzh.ch 15	  
 16	  
The study was performed at the Clinic for Small Animal Internal Medicine and Institute of 17	  
Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Switzerland. 18	  
 19	  
Acknowledgments: This study was partially supported by a grant from Nestlé Purina 20	  
PetCare. 21	  
22	  
	   2	  
Abstract 22	  
Background―Cats with diabetes mellitus frequently achieve clinical remission, suggesting 23	  
some residual β-cell function. The intravenous arginine stimulation test (ivAST) is used to 24	  
elicit insulin and glucagon secretion. Responsiveness of β-cells to arginine has been shown to 25	  
decrease the last during diabetes progression. 26	  
Hypothesis―Diabetic cats with and without remission have different arginine-induced 27	  
insulin or glucagon response. 28	  
Animals―17 cats with newly diagnosed diabetes, 7 healthy cats. 29	  
Methods―Blood samples were collected on admission and during subsequent ivAST. 30	  
Glucose, insulin and glucagon were measured. Response to ivAST was assessed by 31	  
calculating the insulin and glucagon area under the curve (AUC) and the AUC glucagon-to-32	  
insulin ratio. Diabetic cats were treated with insulin and were followed-up for 18 weeks. 33	  
Remission was defined as normoglycemia and disappearance of clinical signs of diabetes for 34	  
≥4 weeks, without requiring insulin. 35	  
Results―Seven diabetic cats (41%) achieved remission. On admission, blood glucose 36	  
concentration was significantly lower in cats with remission (median: 389 mg/dL; range: 342-37	  
536) than in those without (median: 506 mg/dL; range: 266-738). Following ivAST, diabetic 38	  
cats with remission had higher AUC glucagon-to-insulin ratio (median: 61; range: 34-852) 39	  
than cats without (median: 26; range: 20-498); glucose, insulin and glucagon AUCs were not 40	  
different. Diabetic cats had lower insulin AUC than healthy cats but comparable glucagon 41	  
AUC. 42	  
Conclusions and clinical Importance―Diabetic cats with and without remission have 43	  
similar arginine-stimulated insulin secretion on admission. Even though cats with remission 44	  
had lower blood glucose on admission and higher AUC glucagon-to-insulin ratio, large 45	  
overlap between groups prevents use of these parameters in clinical practice. 46	  
 47	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Key-words: feline, insulin, glucagon, prediction, normoglycemia. 48	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List of abbreviations: 50	  
DM: diabetes mellitus; ivAST: intravenous arginine stimulation test; G0, I0 and Gl0: glucose, 51	  
insulin and glucagon concentrations before arginine stimulation, respectively; IPR and GlPR: 52	  
insulin and glucagon peak response, respectively; AUC: area under the curve. 53	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Diabetes mellitus (DM) is one of the most common endocrinopathies in cats and its incidence 54	  
is increasing due to a rise in predisposing factors, such as obesity and physical inactivity.1,2 55	  
Most cats seem to suffer from a Type 2-like form of DM that is characterized by reduced 56	  
insulin secretion and insulin resistance. In up to 50% of diabetic cats, insulin therapy can be 57	  
withdrawn within 4 months after beginning of treatment.3-6 This phenomenon, called diabetic 58	  
remission, is thought to be due to recovery of β-cell dysfunction or of impaired β-cell viability 59	  
induced by the resolution of glucose toxicity.7 60	  
Several insulin secretagogue tests have been evaluated for measurement of insulin secretion 61	  
capacity in humans, including the hyperglycaemic clamp, the intravenous and oral glucose 62	  
tolerance tests, the intravenous glucagon stimulation test and the intravenous arginine 63	  
stimulation test (ivAST).8-12 In Type 1 or 2 diabetic humans, β-cells show progressive 64	  
deterioration in their responsiveness to various secretagogues (i.e., glucose, glucagon and 65	  
amino acids).13,14 Responsiveness towards amino acids has been shown to outlast other 66	  
stimuli, thus suggesting that ivAST may be used to detect residual β-cell secretion capacity 67	  
late during the progression of DM.15 L-arginine is known to be the most potent insulin 68	  
secretagogue of all amino acids. It increases β-cell secretion via membrane depolarization and 69	  
a subsequent rise of intracellular calcium.16 Apart from β-cells, L-arginine also stimulates 70	  
pancreatic α-cell secretion through a similar mechanism.12 71	  
Only one study has investigated residual insulin secretion capacity in cats with DM;4 72	  
however, the glucagon stimulation test failed to show significant differences in insulin 73	  
response between cats that achieved diabetic remission and those that did not.4 74	  
The ivAST has so far been investigated in healthy cats and was shown to be a valuable tool 75	  
for evaluating the insulin secretion capacity;17,a the test was also used for simultaneous 76	  
stimulation of α-cells, thus yielding information about glucagon secretion. Until now the 77	  
ivAST has not been used in diabetic cats, and it is therefore unknown whether it may help 78	  
differentiating between cats that achieve diabetic remission and those that do not, during the 79	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course of treatment. Therefore, the objectives of this study were to perform the ivAST in 80	  
healthy cats and compare results for insulin and glucagon to that obtained in diabetic cats at 81	  
the time of first admission, and to evaluate if differences in the response to arginine exist in 82	  
cats with DM that will achieve remission from those that will not. 83	  
84	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Materials and Methods 84	  
Cats 85	  
Healthy control and diabetic cats were included in the study. Seven neutered male, healthy 86	  
domestic shorthair catsb were used following principles of laboratory animal care (Veterinary 87	  
Office of Zurich, Switzerland, permission Nr. 213/2003). Control cats had a median age of 15 88	  
months (range: 16-24) and were healthy based on physical examination and routine clinical 89	  
laboratory data; cats were lean according to body condition score and their median body 90	  
weight was 4.8 kg (range: 4.5-5.2). Cats had free access to water and were fed twice daily 91	  
with a commercial dietc given at maintenance. 92	  
Cats admitted to the Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University 93	  
of Zurich between September 2004 and May 2008 were considered if DM was diagnosed. A 94	  
diagnosis of DM was based on clinical signs (e.g., polyuria, polydipsia, weight loss), 95	  
hyperglycemia (fasting blood glucose > 180 mg/dL), glucosuria and elevated serum 96	  
fructosamine concentrations (> 340 µmol/L). Diabetic cats were only included if relevant 97	  
concurrent illness (e.g., diabetic ketoacidosis, heart failure, kidney failure, hyperthyroidism) 98	  
was absent and if they had not received insulin prior to admission. To be included in the 99	  
study, all cats had to have a follow-up of at least 18 weeks. 100	  
 101	  
Study design 102	  
In healthy cats a central venous catheter was implanted in the jugular vein on the day prior to 103	  
ivAST; the procedure was carried out under general anesthesia. In diabetic cats, after routine 104	  
work-up performed on admission, a central venous catheterd was placed in the saphenic vein 105	  
under general anesthesia. 106	  
The ivAST was performed on the day after implantation of the central venous catheter in 107	  
overnight fasted cats. Diabetic cats received intravenous fluids (0.9% NaCl at 1 ml/kg/h 108	  
supplemented with 20 mEq of KCl per liter of NaCl) to minimize the risk of development of 109	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ketoacidosis. A baseline blood sample was collected and thereafter argininee was infused 110	  
slowly (over 1 min) via a cephalic vein at a dose of 0.2 g/kg body weight.17 Blood samples 111	  
were obtained after 2, 4, 7, 9, 15, 25 and 30 min via the central venous catheter. Baseline 112	  
samples and samples collected after arginine injection were immediately placed in ice-cold 113	  
EDTA tubes containing aprotininef and centrifuged within 5 min following the test. Plasma 114	  
was stored at -80°C until further use. At baseline, glucose (G0), fructosamine, insulin (I0) and 115	  
glucagon (Gl0) were measured, and the Gl0-to-I0 ratio was calculated. Insulin and glucagon 116	  
responses to ivAST were assessed by determining the insulin and glucagon peak response 117	  
(IPR and GlPR, respectively) above baseline, by calculating the insulin and glucagon area 118	  
under the curve (AUC) during the initial 9 min (AUC9) and the entire 30 min (AUC30) of 119	  
stimulation, and by calculating the AUC9 and AUC30 glucagon-to-insulin ratio. The reason for 120	  
calculating the AUC9, in addition to AUC30, is that the highest response to arginine has been 121	  
demonstrated during the first 9 min following injection in cats.17 Insulin-to-glucagon ratios 122	  
were calculated because it has been shown that a close interplay exists between α-and β-cells 123	  
in mice and rats, with glucagon being one possible α-cell product necessary for normal β-cell 124	  
secretion.18 125	  
 126	  
Treatment of cats with DM 127	  
After recovery from the ivAST, diabetic cats were discharged and prescribed subcutaneous 128	  
routine treatment with insulin, either porcine insulin zinc suspensiong or insulin glargineh, 129	  
according to the following scheme: starting dose in cats ≤ 4 kg 1 U, q12h, in cats > 4 kg 1.5-2 130	  
U, q12h. In addition, a specific commercial dietc was recommended. Follow-up examinations 131	  
were performed after 1, 3, 6, 10 and 18 weeks from admission and included assessment of 132	  
clinical signs and body weight, measurement of a biochemical profile with serum 133	  
fructosamine and generation of a blood glucose curve. The latter was performed by measuring 134	  
capillary blood glucose every 2 hours, over 10-12 hours, as previously described.19 Insulin 135	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dose was adjusted to improve glycemic control, if necessary. The diet was changed if the cat 136	  
developed renal failure, diarrhea, or food aversion. 137	  
 138	  
Cats with and without remission of DM 139	  
Diabetic cats that did not require insulin administration to keep normoglycemia for at least 4 140	  
weeks during the follow-up period were defined as being in remission.20 Cats that required 141	  
insulin throughout the study were defined as not being in remission. 142	  
 143	  
Analytical procedures 144	  
Complete blood counts, serum biochemical profile and urinalysies were performed using 145	  
standard laboratory methods. Plasma glucose and serum fructosamine were measured by 146	  
means of an automatic analyzeri with commercial reagentsj. Insulin and glucagon were 147	  
measured by commercial radioimmunoassayk,l previously validated in our laboratory.21,22 148	  
Insulin inter-assay and intra-assay coefficients of variation were 7.0% and 6.5%, respectively; 149	  
the sensitivity of the assay was 2 µU/mL. Glucagon inter-assay and intra-assay coefficients of 150	  
variation were 8.2% and 7.5%, respectively; the sensitivity of the assay was 50 pg/mL. 151	  
 152	  
Statistical analysis 153	  
Results are expressed as median and range. Characteristics of diabetic cats, including body 154	  
weight, blood glucose and fructosamine concentrations on admission, and prescribed dosage 155	  
of insulin at discharge were compared between cats that achieved remission and those that did 156	  
not with the Mann Whitney U-test. The same test was used to compare results of the ivAST in 157	  
healthy and diabetic cats and in diabetic cats with and without remission; in particular, 158	  
baseline concentrations of G0, I0 and Gl0, and the Gl0-to-I0 ratio, and, after arginine 159	  
stimulation, the IPR, GlPR, AUC9 and AUC30 of glucose, insulin and glucagon, and the AUC9 160	  
and AUC30 of glucagon-to-insulin ratios. 161	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To assess whether initial body weight, blood glucose and fructosamine concentrations at the 162	  
time of admission differed between diabetic cats with and without remission after 18 weeks of 163	  
treatment the Wilcoxon matched paired test was used. 164	  
Results were significantly different at p<0.05. Statistical analysis was performed with a 165	  
software.m 166	  
167	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Results 167	  
Cats with DM 168	  
Seventeen diabetic cats met the inclusion criteria. Median age was 12 years (range: 8-17). On 169	  
admission median body weight was 5.7 kg (range: 2.9-10). Eleven cats were neutered male 170	  
and 6 spayed female; they were all domestic shorthair. Fasting blood glucose was 437 mg/dL 171	  
(range: 266-738) and fructosamine was 666 µmol/L (range: 580-895). All cats showed severe 172	  
glucosuria; none had ketonuria or positive urine culture. 173	  
Seven cats (41.2%) experienced diabetic remission during the study period whereas remission 174	  
did not occur in 10 cats (58.8%) (Table 1). Insulin in cats with remission could be 175	  
discontinued after a median time of 8 weeks (range: 6-14). Age in cats with and without 176	  
remission was similar. On admission, body weight was not different between groups and, 177	  
within each group, did not significantly change after 18 weeks compared to baseline. At 178	  
diagnosis blood glucose was approximately 25% lower in cats that achieve remission, while 179	  
fructosamine did not differ (Table 1). Blood glucose and fructosamine concentrations were 180	  
significantly decreased in both groups after 18 weeks compared to admission. In all cats with 181	  
remission blood glucose and fructosamine concentrations were within normal limits after 182	  
discontinuation of insulin therapy. 183	  
Eight cats (5 with remission, 3 without remission) were treated with porcine insulin zinc 184	  
suspensiong and 9 (2 with remission, 7 without remission) with insulin glargineh. The initial 185	  
insulin dose was not significantly different for cats with and without remission. 186	  
 187	  
ivAST in healthy cats and cats with DM 188	  
Results of the ivAST in healthy and diabetic cats are reported in Table 2. Cats with DM had 189	  
significantly higher G0 and glucose AUC9 and AUC30 than healthy cats, whereas I0, IPR and 190	  
insulin AUC9 and AUC30 were significantly lower. Gl0, GlPR and the glucagon AUC9 and 191	  
AUC30 were not different between healthy and diabetic cats. Of note, glucagon AUC9 and 192	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AUC30 of 5 diabetic cats (4 with remission and 1 without remission) were 2- to 4-times higher 193	  
than that of all healthy cats. The Gl0-to-I0 ratio was not different between healthy and diabetic 194	  
cats, whereas the AUC9 and AUC30 glucagon-to-insulin ratio were significantly higher in the 195	  
latter group. Insulin and glucagon response to arginine in healthy cats and cats with DM are 196	  
shown in Figure 1. 197	  
 198	  
ivAST in cats with and without remission of DM 199	  
Results of the ivAST in diabetic cats that achieved remission and in those that did not, are 200	  
reported in Table 3. Differences were not observed between the two groups for G0, glucose 201	  
AUC9 and AUC30, I0, IPR, insulin AUC9 and AUC30, Gl0, GlPR, glucagon AUC9 and the Gl0-202	  
to-I0 ratio. For glucagon AUC30 and the AUC9 glucagon-to-insulin ratio a trend towards an 203	  
increase in cats with remission was observed. The AUC30 glucagon-to-insulin ratio was 204	  
significantly higher in cats with remission. Insulin and glucagon response to arginine in 205	  
diabetic cats with and without remission are shown in Figure 2. 206	  
207	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Discussion 207	  
In the present study we showed that the insulin response to arginine was similar between cats 208	  
with newly diagnosed DM that achieved remission or that did not. In addition, we observed 209	  
that baseline glucose concentrations and the AUC30 glucagon-to-insulin ratio after arginine 210	  
stimulation were higher in diabetic cats with remission, although a large overlap with cats that 211	  
continuingly required insulin existed. We also showed that diabetic cats, compared to healthy, 212	  
had decreased insulin but comparable glucagon secretion following ivAST. 213	  
Based on the notion that the insulin secretory response to arginine persists longer than to 214	  
glucose and glucagon in diabetic humans,13-15 we hypothesized that the ivAST used at 215	  
admission may unveil cats with DM achieving remission. However, different to our 216	  
hypothesis, insulin secretion following arginine was similar between diabetic cats, suggesting 217	  
that the test is not sensitive enough to identify cats with residual β-cell function. Arginine-218	  
induced glucagon secretion was also comparable between diabetic cats, although it tended to 219	  
be higher in cats with remission, as shown by the slightly increased AUC9 and AUC30 220	  
(p=0.089 and 0.055, respectively). Notably, the AUC30 glucagon-to-insulin ratio was 221	  
significantly higher (approximately 2.5-fold) in cats that achieved remission compared to cats 222	  
that continued to receive insulin. A trend towards significance was observed by calculating 223	  
the above ratio during the first 9 min of arginine stimulation. The reason why diabetic cats 224	  
with remission have increased secretory reserve of glucagon relative to insulin may appear 225	  
elusive, especially considering that the former hormone is diabetogenic, being a potent 226	  
stimulator of hepatic glycogenolysis and gluconeogenesis.23 However, pancreatic α-cells seem 227	  
to be required to maintain β-cell glucose competence via glucagon.24 Indeed, glucagon 228	  
receptor knock-out mice have impaired β-cell function.25 Further, a transgenic mice 229	  
overexpressing glucagon receptor in β-cells confirmed this concept, as the model showed 230	  
improved glucose tolerance and increased insulin secretion in response to glucose.26 Whether 231	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the present findings in cats suggest a direct role for glucagon in supporting β-cells and insulin 232	  
secretion remains unknown. 233	  
Compared to diabetic cats that required insulin during the study period, we found that the 234	  
degree of hyperglycemia on first admission was lower in cats undergoing remission. This 235	  
result may suggest that the blood glucose concentrations are linked to the propensity for 236	  
clinical recovery of DM in cats. Possibly, excessive hyperglycemia led to severe and 237	  
irreversible toxicity in cat β-cells,21 eventually preventing remission. However, similar 238	  
concentrations of serum fructosamine were found in cats with or without remission, implying 239	  
that the average degree of hyperglycemia during the weeks prior to diagnosis was comparable 240	  
in the two groups. Furthermore, different from the present results, in another study performed 241	  
at our institution, diabetic cats with and without remission had similar glucose concentrations 242	  
at first diagnosis.6 The reason underlying the lower grade of hyperglycemia in the present cats 243	  
that later did not need insulin, remains unanswered. 244	  
Compared to healthy controls, and not unexpectedly, all diabetic cats had lower I0. Arginine-245	  
induced insulin secretion was also decreased, as shown by lower IPR and insulin AUC9 and 246	  
AUC30, suggesting β-cell dysfunction. Impaired insulin secretion may be due β-cell 247	  
exhaustion or decreased insulin gene expression.21 Because in pancreatic sections of diabetic 248	  
cats a severe decrease of islet cells is consistently observed,27 β-cell loss may also have partly 249	  
contributed to decrease insulin secretion. 250	  
Arginine is known to stimulate glucagon release in humans and rodents.28 This mechanism is 251	  
believed to prevent hypoglycemia secondary to aminogenic insulin secretion by increasing 252	  
hepatic gluconeogenesis.29 We could not observe increased glucagon concentrations 253	  
following arginine (0.2 g/kg) in healthy cats, because concentration of GlPR was similar to 254	  
that of Gl0. The reason for this finding is unclear since it was previously shown that arginine 255	  
at 0.1 g/kg stimulated glucagon in healthy cats.17 In diabetic cats glucagon secretion was not 256	  
different compared to healthy cats. Differently from recent findings demonstrating a positive 257	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role for glucagon in β-cells, it was hypothesized that glucagon may be detrimental because it 258	  
is associated with hyperglycemia in diabetic humans and rodent models;30 glucagon 259	  
concentrations are often elevated in various forms of DM in these species.31-33 Worth 260	  
mentioning, 5 diabetic cats had increased glucagon AUC9 and AUC30, suggesting that in some 261	  
cases DM is associated with elevated glucagon response to arginine, as in humans and 262	  
rodents. Because 4 of these 5 diabetic cats later achieved remission, an increased arginine-263	  
induced α-cell response may be linked to a favourable outcome in feline DM. 264	  
There are some limitations of this study that need to be mentioned. Diabetic cats were treated 265	  
with either porcine insulin zinc suspensiong or insulin glargineh, possibly leading to bias in the 266	  
results. In particular, as recently described, cats receiving insulin glargine may have an 267	  
increased chance of remission.34 However, in our series only 2 of the 9 (22.2%) diabetic cats 268	  
treated with insulin glargine achieved remission, compared to 5 of the 8 (62.5%) diabetic cats 269	  
that were administered porcine insulin zinc suspensiong. Thus, the potential beneficial effect 270	  
of insulin glargine likely did not influence the frequency of remission in the present series. 271	  
Each of the diabetic cats was evaluated for 18 weeks after diagnosis. It cannot be excluded 272	  
that some of the cats would have achieved remission after that period, if followed-up for 273	  
longer. However, it is known that the large majority of diabetic cats achieving remission have 274	  
insulin therapy discontinued within the first 4 months of treatment.3-6 Thus, the risk of having 275	  
included diabetic cats with remission in the group kept on insulin during the 18-week of the 276	  
study may be small. 277	  
In summary, the similar arginine-stimulated insulin response in diabetic cats with and without 278	  
remission suggests that the ivAST cannot be used to predict those cats with remaining 279	  
sufficient β-cell function at diagnosis. The higher AUC30 glucagon-to-insulin ratio observed 280	  
in diabetic cats that did not require insulin to maintain normoglycemia may indicate that a 281	  
relative increase of α-cell function is involved in the mechanisms leading to remission. Lower 282	  
degree of hyperglycemia on admission in cats with remission has not been previously 283	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reported and necessitates additional confirmation. Unfortunately, the large overlap between 284	  
results of the AUC30 glucagon-to-insulin ratio and blood glucose concentrations prevents the 285	  
use of these parameters to reliably predict diabetic cats with remission in clinical practice. 286	  
 287	  
Footnotes 288	  
aLink KR, Rand JS. Arginine and phentolamine response test in cats. J Vet Intern Med 289	  
1996;146:185 (abstract) 290	  
bHarlan Sprague Dawley, Indianapolis, IN 291	  
cDM Purina Veterinary diets, Nestlé-Purina, Vevey, Switzerland 292	  
dCareflow, Becton Dickinson, Basel, Switzerland  293	  
eL-arginin-hydrochlorid 21%, B-Braun, Sempach, Switzerland 294	  
fTrasylol, 500 KIU/ml, Bayer Pharmaceuticals Corporation, Geneva, Switzerland 295	  
gCaninsulin, Intervet International BV, Boxmeer, the Netherlands 296	  
hLantus, Sanofi Aventis, Meyrin, Switzerland 297	  
iCobas Integra, Roche, Basel, Switzerland 298	  
jGlucose and fructosamine, Roche, Basel, Switzerland 299	  
kLinco Porcine Insulin RIA Kit, Millipore, Zug, Switzerland 300	  
lGlucagon ICN Biomedicals, MP Biomedicals Europe, Basel, Switzerland 301	  
mGraphPad Prism 4, GraphPad Software Inc, San Diego, CA 302	  
303	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Figure legends 382	  
 383	  
Figure 1. (A) Insulin and (B) glucagon concentrations after arginine injection in healthy cats 384	  
(white dots) and cats with DM (black dots). Median and interquartile range are shown. 385	  
 386	  
Figure 2. (A) Insulin and (B) glucagon concentrations after arginine injection in diabetic cats 387	  
that achieved (white dots) or not (black dots) remission. Median and interquartile range are 388	  
shown. 389	  
